Drug Trial Radar · NCT07052032
An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
47
Planned (sponsor's estimate)
Start
Jun 16, 2025
Primary completion
Jun 1, 2027
Study completion Jun 1, 2027
Sponsor
- Lead sponsor
- Candid TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety and efficacy of CND261 in patients with seropositive rheumatoid arthritis.
Conditions
- Rheumatoid Arthritis
Interventions
CND261Biological
CND261 will be dosed according to the assigned cohort
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse events through end of studyTime frame: Baseline to Month 12
- Changes from baseline in vital signs through end of studyTime frame: Baseline to Month 12
- Changes from baseline in ECG parameters through end of study: PR intervalTime frame: Baseline to Month 12
- Changes from baseline in ECG parameters through end of study: QRS intervalTime frame: Baseline to Month 12
- Changes from baseline in ECG parameters through end of study: QTcF intervalTime frame: Baseline to Month 12
- Changes from baseline in safety laboratory assessments through end of studyTime frame: Baseline to Month 12
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Candid Clinical Site
Chisinau, Moldova
Candid Clinical Site
Kyiv, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.